<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Supriya Lifescience has submitted its annual disclosure to BSE confirming that the company does not qualify as a 'Large Corporate' under SEBI's framework for the financial year ended March 31, 2025. The Large Corporate classification applies to listed entities that meet specific borrowing thresholds set by SEBI. By confirming it falls below these thresholds, Supriya indicates its outstanding borrowings are under the SEBI-mandated limit (currently Rs 1,000 crore for non-financial companies). The disclosure was signed by Prachi Sathe, Company Secretary & Compliance Officer, on April 28, 2025, and references SEBI circulars from August 2021, April 2022, and October 2023.
This is a routine compliance filing with no material impact on shareholders. It signals that Supriya Lifescience's debt levels remain well below SEBI's Large Corporate threshold, meaning no mandatory incremental borrowing or qualified institutional placement requirements are triggered for the company.